Supplementary Materials

This PDF file includes:

• Materials and Methods
• Fig. S1. Syntheses of LSN3316612, amine precursor 7, and nitro precursor 10.
• Fig. S2. Chemical structure and ¹H, ¹³C, and ¹⁹F NMR spectra for compound 2.
• Fig. S3. Chemical structure and ¹H, ¹³C, and ¹⁹F NMR spectra for LSN3316612.
• Fig. S4. Chemical structure and ¹H, ¹³C, and ¹⁹F NMR spectra for compound 6.
• Fig. S5. Chemical structure and ¹H, ¹³C, and ¹⁹F NMR spectra for amine precursor 7.
• Fig. S6. Chemical structure and ¹H and ¹³C NMR spectra for compound 9.
• Fig. S7. Chemical structure and ¹H and ¹³C NMR spectra for nitro precursor 10.
• Fig. S8. Synthesis of [³H]LSN3316612.
• Fig. S9. Saturation radioligand binding to brain regions using [³H]LSN3316612.
• Fig. S10. [³H]LSN3316612 binding to postmortem human AD and control brain tissue.
• Fig. S11. Radiometabolite analyses for [¹¹C]LSN3316612 and [¹⁸F]LSN3316612.
• Fig. S12. Chromatograms from the radio-HPLC separation of [¹¹C]LSN3316612.
• Fig. S13. Chromatograms from the radio-HPLC quality control of [¹¹C]LSN3316612.
• Fig. S14. Chromatograms from the radio-HPLC separation of [¹⁸F]LSN3316612.
• Fig. S15. Chromatograms from the radio-HPLC quality control of [¹⁸F] LSN3316612.
• Table S1. Radioactivity concentration of [³H]LSN3316612 in brain sections of monkey or human.
• Table S2. Biometric information for human participants.
• Table S3. Individual V_T in four brain regions for all human participants.

[Download PDF]